Negotiating for public-health driven licences with patent holders is the core work of the Medicines Patent Pool. Below is a list of the current licences in the MPP Pool. Signed sub-licensing agreements are linked where applicable.
The Medicines Patent Pool announced on 5 August 2013 an agreement with Swiss pharmaceutical company Roche to increase access to valganciclovir, a key easy-to-take oral medicine to treat cytomegalovirus (CMV), a viral infection that can cause blindness in people living with HIV. This agreement is unique in being a two-phased approach to better treat the infection. First, an agreement that will significantly improve access to Roche’s valganciclovir for people living with HIV in 138 developing countries by making it up to 90% cheaper than current prices. As a second step, the Medicines Patent Pool and Roche will enter into licensing and technology transfer negotiations to encourage the development of internationally approved quality generic versions of valganciclovir.
The full signed text of the agreement is available below:
ViiV Healthcare [GlaxoSmithKline, Pfizer, Shionogi]
The Medicines Patent Pool announced on 27 February 2013 a collaboration with ViiV Healthcare. The collaboration consists of a Memorandum of Understanding. The Memorandum of Understanding sets out commitments between MPP and ViiV Healthcare to collaborate in several areas with the ultimate goal of making more quality and affordable medicines for children available. These areas include: a commitment from ViiV Healthcare to license its pipeline products for paediatric use in 118 countries once they are approved by drug regulatory authorities; provide technology transfer to aid in generic manufacture; access to data on medicines quality and efficacy; and planned partnerships with third-party stakeholders to help bring to market as-yet undeveloped new treatments, and to speed the availability of those treatments in developing countries. The MOU also contains a legally-binding licence on paediatric abacavir for use in the 118 countries where most children with HIV live.
The full, signed texts of the memorandum of understanding and the licence agreement are available below:
- Memorandum of Understanding [pdf]
- Abacavir Licence [pdf]
- Form Sublicence Agreement for Abacavir [pdf]
- Aurobindo Pharma [pdf]
The Medicines Patent Pool signed a licence agreement with Gilead Sciences in July 2011. It was the first agreement the Pool has made with a pharmaceutical company patent holder.
The licences are in three documents, available below. The first is the primary licensing agreement signed by the Pool and Gilead. This agreement dictates that the Pool use the following two forms in its sub-licensing to generic companies. The first sub-licence document is a form “amended and restated” for existing Gilead sublicensees. The second is a form sub-licence agreement for new sublicensees.
Since its signing, the agreement has been amended four times:
- On 1 November 2012 [pdf], an amendment was signed adding the obligation for Gilead to transfer certain technology related to the manufacture of emtricitabine
- On 26 July 2012 [pdf], an amendment was signed removing any royalty payments due to the Pool as a result of the agreement.
- On 14 November 2011, the Pool and Gilead signed a set of amendments clarifying issues raised by civil society after the licences were announced.
- On 19 July 2011 [pdf], the Pool and Gilead signed an amendment to the licensing agreement to include the then newly-formed South Sudan in the geographical scope.
The licensing agreement texts linked below reflect these above listed amendments.
- Main licensing agreement between the Pool and Gilead [pdf]
- Amended and Restated Licence Agreement [pdf]
- Form Sublicence Agreement [pdf]
- Shilpa Medicare [pdf]
- Shasun Pharma Solutions [pdf]
- Aurobindo Pharma Limited [pdf]
- Emcure Pharmaceuticals [pdf]
- Hetero Labs [pdf]
- Laurus Labs [pdf]
US National Institutes of Health
The Medicines Patent Pool received its first licences from the US National Institutes of Health for patents related to the HIV medicine darunavir in September 2010.